Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Cocoa Prices Sink on Favorable Crop Conditions in West Africa - 2Nations for Youngsters to Visit
- 3Artemis II updates: NASA's moon mission breaks Apollo record for farthest distance humans have traveled from Earth
- 4Dependable Savvy Locks to Update Your Home Security
- 5Top 5 Top of the line Books of the Year
- Independence from the rat race: How to Save and Contribute Shrewdly
- Holiday travel: Best days to hit the road as 110 million Americans expected to drive over Christmas and New Year's
- NASA counts down for first crewed lunar mission in half a century
- We may have less control over how long we live than previously thought
- Chicago reports first rabies-positive dog in 61 years. What we know.
- Here's what the Artemis 2 astronauts will be doing on each day of NASA's historic moon mission
- Bennu asteroid samples provide clues about solar system origins and 'space gum'
- Australian State Triggers Emergency Powers Amid Fuel Crisis
- Cells have more mini ‘organs’ than researchers thought − unbound by membranes, these rogue organelles challenge biology’s fundamentals
